Today's Veterinary Business

AUG 2018

Today’s Veterinary Business provides information and resources designed to help veterinarians and office management improve the financial performance of their practices, allowing them to increase the level of patient care and client service.

Issue link:

Contents of this Issue


Page 48 of 75

Guide to Client Conversations PUREVAX vaccines are manufactured by Merial. Merial is now part of Boehringer Ingelheim. PUREVAX ® is a registered trademark of Merial. ©2018 Merial, Inc., Duluth, GA. All rights reserved. PET-0526-PUR0718. 1 Green CE. Immunoprophylaxis and immunotherapy. In: Green CE, ed. Infectious Diseases of the Dog and Cat. 3rd ed. Philadelphia: WB Saunders Co., 2006: p.1073-1077 and p.1096. 2 Taylor J, Meignier B, Tartaglia J, et al. Biological and immunogenic properties of canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species. Vaccine. 1995;13;6;539-549 3 Day MJ, Schoon H-A, Magnol J-P, et al. A kinetic study of histopathological changes in the subcutis of cats injected with non- adjuvanted and adjuvanted multi-component vaccines. Vaccine. 2007;25:4073-4084. Cats take enough risks on their own. Why add adjuvanted vaccines to the list? FEATURE: PUREVAX® provides safe, pure, proven protection. » BENEFIT: The modified-live and recombinant technologies found in PUREVAX vaccines: • Provide rapid protection 1,2 • Deliver targeted protection without the use of adjuvants 1,2 • Stimulate a balanced immune response involving cell-mediated and humoral (antibody) responses 1,2 FEATURE: PUREVAX RECOMBINANT vaccines use canarypox-vectored technology. » BENEFIT: Canarypox-vectored vaccines contain only a portion of the genetic material of a pathogen, not the complete pathogenic organism. Therefore there is no potential reversion to virulence. FEATURE: The only complete line of nonadjuvanted feline vaccines. » BENEFIT: PUREVAX vaccines provide protection and reduce the potential risks associated with adjuvants, including: • Injection site reaction 1,3 • Injection site granuloma 3 • Chronic inflammation 3

Articles in this issue

Archives of this issue

view archives of Today's Veterinary Business - AUG 2018